The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Ascendis Pharma Launches YUVIWEL in U.S. for Pediatric Achondroplasia

Key Facts

1Ascendis Pharma launched YUVIWEL, the first once-weekly treatment for children with achondroplasia in the U.S.

2The treatment received orphan drug exclusivity until February 27, 2033.

Version History

1 additional source confirmed this story

Ascendis Pharma has officially launched YUVIWEL (navepegritide) in the United States, marking a significant milestone in pediatric healthcare. The treatment is the first once-weekly growth therapy approved for children aged two and older suffering from achondroplasia. This commercial rollout follows FDA approval and includes a seven-year orphan drug exclusivity period lasting until February 27, 2033. The company confirmed that revenue recognition has already commenced following the initiation of therapy for the first group of patients. This launch provides a less frequent dosing alternative compared to existing daily treatments, potentially improving patient compliance and clinical outcomes. Investors view this development as a major catalyst for the company's long-term growth and market positioning within the biotechnology sector.